Cite
Medic G, Korchagina D, Young KE, et al. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. J Mark Access Health Policy. 2017;5(1):1299665doi: 10.1080/20016689.2017.1299665.
Medic, G., Korchagina, D., Young, K. E., Toumi, M., Postma, M. J., Wille, M., & Hemels, M. (2017). Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. Journal of market access & health policy, 5(1), 1299665. https://doi.org/10.1080/20016689.2017.1299665
Medic, Goran, et al. "Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe." Journal of market access & health policy vol. 5,1 (2017): 1299665. doi: https://doi.org/10.1080/20016689.2017.1299665
Medic G, Korchagina D, Young KE, Toumi M, Postma MJ, Wille M, Hemels M. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. J Mark Access Health Policy. 2017 Apr 10;5(1):1299665. doi: 10.1080/20016689.2017.1299665. eCollection 2017. PMID: 28473888; PMCID: PMC5405566.
Copy
Download .nbib